AU758126B2 - Delivery system for porcine somatotropin - Google Patents

Description

WO 00/23601 PCT/AU99/00896 1 DELIVERY SYSTEM FOR PORCINE SOMATOTROPIN Field of the Invention: The present invention relates to an expression construct for delivering an exogenous polypeptide to a host. The present invention also relates to recombinant cells which include this expression construct and to semipermeable capsules which include the recombinant cells.

Background of the Invention: In mammals, somatotropin (growth hormone) is normally secreted from the pituitary gland. However, exogenous administration of somatotropin to pigs has been shown to improve feed efficiency 15-20%, increase daily weight gain 10-15%, reduce carcass fat 10-20%, increase lean meat content 5-10% and reduce feed intake. Unfortunately, somatotropin (which is a small protein of 190 amino acids) is susceptible to gastric acids and protein digestion hence daily injections are required in order to be efficacious. Currently, welfare and ethical issues discourage the use of the pneumatic pST injection gun and the costs of daily administration restrict industry-wide adoption.

Recent advances in gene therapy have enabled the development of strategies which avoid the dependence on autologous target cells and immunosuppressive therapy by utilising transfected cells encapsulated in a semi-permeable alginate-poly-L-lysine-alginate (APA) membrane. The APA capsule environment is compatible with cell viability and growth so that transfected cells remain viable, secreting growth factors, for extended periods. The APA is permeable to small proteins and consequently gene expression can be controlled by external means. The APA barrier inhibits immune surveillance and cell rejection events so that non-host, highly expressing, cells can be employed in the capsule. The APA barrier may also prevent uncontrolled proliferation of the transfected cells in the recipient host. The APA capsule can be removed, potentially re-used, in order to negate the concerns regarding consumption of transgenic material. Further, if the capsule is damaged by severe tissue trauma a normal host-graft rejection would destroy the implanted cells.

WO 00/23601 PCT/AU99/0089 6 2 Summary of the Invention: The present inventors have now found that ligation of an insulin secretory signal to a heterologous gene sequence prior to introduction of the gene sequence into a host cell results in a surprising increase in the level of secretion of the heterologous gene product. This finding has led to the development of an improved gene delivery system involving encapsulation of recombinant cells for implantation into a host.

Accordingly, in a first aspect, the present invention provides an expression cassette including a sequence encoding an insulin secretory signal operably linked to a heterologous sequence encoding a polypeptide.

By "heterologous sequence" we mean a sequence other than a sequence encoding insulin.

By "operably linked" we mean that the insulin secretory signal sequence is contiguous and in reading frame with the heterologous coding sequence.

The preferred insulin secretory signal is an insulin secretory signal having the amino acid sequence shown as SEQ ID NO:1. However, it will be appreciated by those skilled in the art that a number of modifications may be made to that secretory signal without deleteriously affecting the biological activity of the signal. For example, this may be achieved by various changes, such as sulfation, phosphorylation, nitration and halogenation; or by amino acid insertions, deletions and substitutions, either conservative or nonconservative (eg. D-amino acids, desamino acids) in the peptide sequence where such changes do not deleteriously affect the overall biological activity of the secretory signal. Thus, the inclusion in the expression cassette of an insulin secretory signal which has been modified in one or more of the abovementioned ways, is to be regarded as being encompassed by the present invention.

The heterologous sequence may encode any polypeptide, other than insulin, of interest. For example, the heterologous sequence may encode a hormone, cytokine, receptor agonist or antagonist, pheromone or enzyme. In a preferred embodiment, the heterologous sequence encodes a growth hormone. Preferably, the growth hormone is somatotropin.

In a second aspect, the present invention provides a vector including an expression cassette of the first aspect. The vector may be any suitable WO 00/23601 PCT/AU99/00896 3 vector for introducing the expression cassette into a cell. Suitable vectors include viral vectors and bacterial plasmids.

The expression cassette of the first aspect of the present invention, or the vector of the second aspect, may further include one or more elements which regulate gene expression. Examples of suitable regulatory elements include the Melatonin Response Element (MRE) (as described in Schrader et al, 1996, the entire contents of which are incorporated herein by reference), and/or rapamycin mediated transcription factors (as described in Magari et al, 1997, the entire contents of which are incorporated herein by reference). In a preferred embodiment, the regulatory element(s) enable pulsatile expression of the polypeptide of interest.

In a third aspect, the present invention provides a recombinant cell which includes an expression cassette according to the first aspect of the present invention.

The recombinant cell may be a bacterial, yeast, insect or mammalian cell. In a preferred embodiment, the recombinant cell is a mammalian cell In a further preferred embodiment, the cell is a rat myoblast (L6) cell.

In a fourth aspect, the present invention provides a method of producing a polypeptide which includes culturing a recombinant cell of the third aspect under conditions enabling the expression and secretion of the polypeptide and optionally isolating the polypeptide.

The recombinant cell(s) of the present invention may be encapsulated in a semi-permeable matrix for delivery or implantation in a host.

Accordingly, in a fifth aspect, the present invention provides a capsule for implantation in a host, the capsule including a semi-permeable membrane which encapsulates one or more recombinant cells according to the third aspect of the present invention.

In a preferred embodiment, the semi-permeable membrane is an alginate-poly-L-lysine-alginate (APA) membrane. The preparation of an APA semi-permeable membrane is described in Basic et al, 1996, the entire contents of which are incorporated herein by reference.

In a sixth aspect, the present invention provides a method of administering a polypeptide to a host which includes administering to the host an expression cassette according to the first aspect of the present invention.

WO 00/23601 PCT/AU99/00896 4 In a seventh aspect, the present invention provides a method of administering a polypeptide to a host which includes implanting in the host a capsule according to the fifth aspect of the present invention.

The host may be any animal or human. In a preferred embodiment, the host is a livestock animal. In a further preferred embodiment, the host is selected from the group consisting of grazing cattle, feed-lot cattle, dairy cows, pigs and poultry.

It will be appreciated by those skilled in the art that the present invention provides an improved system for the delivery of genetic material to a host. The ligation of the insulin secretory signal to a biologically active polypeptide leads to increased secretion of the polypeptide from recombinant cells. Following secretion, the secretory signal may be cleaved leaving the biologically active polypeptide. The recombinant cells, when encapsulated in a semi-permeable membrane, have the capacity to secrete significant amounts of the biologically active polypeptide and the semi-permeable membrane enables control of gene expression by external means.

Implantation of the encapsulated recombinant cells provides an advantage in that the implantation requires minimal surgery. Further, the semi-permeable membrane reduces immune surveillance and cell rejection which means that non-host cells can be employed in the capsule.

In a preferred embodiment, the semi-permeable membrane is durable which provides an advantage in that it may limit cell growth thereby preventing uncontrolled proliferation in the recipient host. The capsules provide a further advantage in that they may be removed and re-used.

In order that the nature of the present invention may be more clearly understood, preferred forms thereof will now be described with reference to the following non-limiting Examples and Figures.

141429719 Brief description of the accompanying figures: Figure 1: Insulin secretory signal pST gene construct.

Figure 2: Insulin secretory signal pST peptide sequence.

Figure 3: Rate of weight gain (from day 0) for control and individual pST-L6IXS treated pigs.

Figure 4: Percentage weight gain for control and individual pST-L6IXS treated animals.

Figure 5: Plasma, pST levels for control and individual pST-L6IXS treated animals.

Figure 6: Plate 1 Appraisal of pST-L6IXS capsule administration site.

S* Plate 2 Placement of pST-L6IXS capsule in cultural media for ex-vivo 010 assessment.

Figure 7: Ex-vivo assessment of secretion of pST from capsules for a 24 hr period 'following removal from host animal.

Figure 8: Mean plasma pST (over 3 hours 30 min intervals) before (white bars) and 1 week post pST capsule administration (black bars) (*significant).

Figure 9: Daily plasma pST concentrations of two pigs, pig 206 and 228, with implanted capsules secreting 25 ng/ml and 500 ng/ml respectively.

Figure 10: Rate of Gain (ROG) in kg/ day (black squares) and P2 back fat measurements Sin pigs produced in Example 4.

Figure 11: Rate of Gain (ROG) of male pigs following implantation with pST secreting or 20 control immunoneutral gene therapy (IGT) capsules SEM).

Figure 12: Back fat (P2) of male pigs following implantation with pST secreting or control immunoneutral gene therapy (IGT) capsules SEM).

S* Figure 13: Loin (eye) muscle area of male pigs following implantation with pST secreting or control immunoneutral gene therapy (IGT) capsules SEM).

Figure 14: Photographs of Enhanced Green Fluorescence Protein (EGFP) fluorescence from L6 cells transfected with an expression construct ISS.

WO 00/23601 PCT/AU99/00896 6 Detailed description of the invention: Example 1: Cloning of the ISS-pST construct The pST gene was obtained from Southern Cross Biotechnology Pty Ltd in an E. coli bacterium. The plasmid containing the pST gene, pMG939, was isolated from the bacterium using standard plasmid preparation techniques. The PCR primers were designed to amplify the pST gene, add an Xho I site to the 5' end and anXba I site to the 3' end to enable ligation events.

The modified pST gene sequence was subsequently ligated to a secretory signal sequence (ISS) derived from the preproinsulin cDNA. Nhe I (GCTAGC) and Xba I (TCTAGA) restriction sites were constructed in front of the ISS start codon and after the 3' terminal codon of pST, respectively, to allow incorporation into the pCI-neo plasmid (Promega). The pST fusion construct was subsequently isolated and sequenced to verify the coding region (Figure 1).

Transfection of rat myoblast (L6) cells (pST gene incorporation into cells) was performed, with LipoTAXI (Stratagene), 2hrs after the L6 cells were trypsin treated. pST transfected L6 cell clones were maintained in culture, selected with G418, until >10 7 cells were generated. Aliquots (2ml) of the culture supernatant were stored at -20 0 C prior to assessment of pST concentrations in a pST radioimmunoassay (RIA) established by Dr P. Wynn at Sydney University (Camden). The RIA sensitivity was deemed to be >0.4ng/ml with CV's in the order of 12.4%. The polyclonal antisera was raised in guinea pigs with a pST peptide antigen. The RIA results (Table 1) indicate that the pST gene construct produced protein (Figure 2) which is recognised by polyclonal antisera raised against the native form of pST, purified from porcine pituitary glands. L6 Clones pCI/pst-1..5 were generated from the modified transfection technique as described below.

Modified transfection protocol Characteristically, L6 cells adhere to culture plates and require detachment with trypsin to passage cells; transfection is routinely performed 24hrs later. This procedure resulted in L6 cell clones (n=10) secreting pST at 6-18 ng/ml. Applying LipoTAXI (Promega) and the ISS/pST plasmid to the L6 cells 2hrs after trypsin treatment increased the secretion rate of pST 10-20 fold (>180ng/ml, n=5 clones). This higher pST secretion rates reduce the number of cells (capsules) required to enhance growth.

WO 00/23601 PCT/AU99/00896 7 TABLE 1: Concentrations (ng/ml) for each clone transfected with ISS-pST.

L6 clone pST (ngml) pCI/pst-1* 182 pCI/pst-2* 188 pCI/pst-3* 188 pCI/pst-4* 140 200 pCI/pst-6 17 pCI/pst-7 12 pCI/pst-8 8 pCI/pst-9 9 7 pCI/pst-11 7 pCI/pst-12 pCI/pst-13 8 pCI/pst-14 6 18 Example 2: Preparation of the porcine somatotropin-rat myoblast (L6) immunoneutral expression system (pST-L61XS) The encapsulation procedure described in Basic et al, 1996, was followed with the following modifications.

Encapsulation of cells at room temperature, utilises calcium chloride (or lactate) [100mM] to gel the alginate w/v] droplets followed immediately by washing with saline NaC1) then resuspending in poly- L-lysine for 5 min. Calcium chloride crosslinking for 10min at 37 0

C

resulted in an alginate matrix that was more compatible with cell viablity.

After the poly-L-lysine coating and saline washes another alginate layer is added. Sodium citrate [55mM] treatment for 4min at room temperature softens the capsule to a consistency that increases the difficulty of further manipulation. Cell viablity is apparently reduced to <35% with 4 min exposure to sodium citrate. Placing the capsules in a cell strainer prior to sodium citrate treatment enabled Imin exposure, at 37 0 C, improving cell viability to >98%.

Procedural and equipment modifications to the encapsulation protocol improved the efficiency (time and resources) of encapsulation with routine increases in cell viability in the order of 64%.

WO 00/23601 PCT/AU99/00896 8 Example 3: Pilot experiment involving implantation of pST-L6IXS in pigs Preliminary results obtained with the pST-L6IXS, administered to growing mice, indicate enhanced growth characteristics. In a pilot experiment with male pigs mean live weight 61 kg) varying numbers of pST-L6IXS were administered in different sites (3 capsules, i.m. in the neck muscle, 3 capsules s.c. in the neck, 10 capsules s.c. at the base of the ear, capsules i.m. in the neck or 29 capsules i.m. in the neck of individual animals on day Blood samples (10ml) were collected via jugular venipuncture and P2 ultra-sound (us) measurements were recorded at -14, 0, 7, 14, 21, 28 and 36 days post administration. The sites of pST-L6IXS administration were monitored for tissue reaction events throughout the experiment. On day 36 animals were euthanased and carcass analysis (back fat depth, BF(mm); eyemuscle area, EMA(cm); forearm bone length, BONE(cm); heart weight, HEART(gm); spleen weight, SPLEEN(gm) and liver weight, LIVER(gm) were recorded (see Table 2) and pST-L6IXS recovered.

Figure 3 represents the rate of gain (from day 0) for control (con, mean+SE, n=4) and individual values for pST-L6IXS treated pigs. Percentage weight gain, over the pST-L6IXS treatment is presented in Figure 4 with the mean+SE for control (con) pigs and individual pST-L6IXS treated animals.

Plasma pST (ng/ml) was determined by radioimmunoassay (RIA) and presented in Figure 5, with mean+SE control (con) and individual concentrations for pST-L6IXS treated pigs. At slaughter the site of pST-L6IXS capsule administration was appraised (Figure 6, Plate 1, arrow) prior to removal and placement in culture media for ex-vivo assessment (Figure 6, Plate 2) of 24 hour secretion of pST (Figure No apparent tissue damage or immune reactions were observed either i.m. or s.c. at day 36.

However, the capsules placed in the ear appeared to be highly vascularised and were 100% recoverable. The capsules placed in the neck region were <10% recoverable.

The pST-L6IXS remained patent over 36 days in vivo and appeared to proliferate within the capsule (Plate 2) which can be removed in order to negate the concerns regarding consumption of transgenic material. Further, if the capsule is damaged by severe tissue trauma) a normal host-graft rejection destroys the L6 cells preventing propagation of transfected material.

Experiments in mice and pigs have demonstrated that pST-L6IXS are WO 00/23601 PCT/AU99/00896 efficacious in altering plasma pST, enhancing growth characteristics and potentially immune competence of animals.

TABLE 2 pST-L61XS PILOT EXPERIMENT: Pigs (male) supplied by Westmill piggery (Young, NSW) Experiment at EMAI, maximum security piggery.

ACEC Ref No: 98/20 LIyE WEIGHT (kg) (slaughter) CARCASS Pell Treatmxent Animnal -14 0 7 14 21 28 30 P2iis BF EMA BONE HEART SPLEEN LIVER (nnl f in (cin) (cm) I gn A con 291 24 67 NR NR 89 95 100 11 9 54.5 24.5 388.5 159.8 1720.2 C A con 292 25 61 NR NR 84 90 90 8 10 54.9 23.7 381.5 103.2 1703.6 C B con 294 22 74_ NR NR 94 103 104 12 15 40.5 24.4. 391.5 173.2 1036.5 C 1B con 295 22 55 1NR NR 76 184 91 9 7 150.6 20.0 396.6 138.2 1561.8 B 3sc neck* 297 23 67 NR NR 85 90 91 9 12 45.2 23.5 385.3 177.0 1817.7 *infected capsule site CvTp<0.05 nsd nsd CvTp<0.06 nsd CvTp<0.05 nsd nsd WO 00/23601 PCT/AU99/00896 11 Example 4: Pilot experiment involving implantation of pST-L6IXS in pigs A second pilot experiment was conducted in order to optimise pST- L6IXS delivery by capsules so as to achieve growth responses similar to the energy repartitioning observed with daily pST injections.

As shown in Example 1, pST secreting cells have been produced with a range of secretion rates (6-200 ng/ml). pST secretion rates in the order of 2ng/ml appear to be the most stable following the imposition of stress (i.e.

by bacterial contamination) on the pST secreting cells (data not shown).

Accordingly, clones secreting about 5 ng/ml (clone pCI/pst-14) and about ng/ml (pCI/pst-12) were selected for this pilot experiment. Male pigs mean live weight 78.1 kg) were administered various numbers of capsules (produced according to the procedure described in Example 2) s.c. at the base of the ear (Table 3).

Pig Capsule Number Clone 204 1 a 216 1 b 230 3 a 202 3 b 226 5 a 206 5 b 208 10 a 224 10 b 222 100 a 228 100 b a clone pCI/pst- 14 (5 ng/ml) b clone pCI/pst-12 (10 ng/ml) Body weights were recorded at the beginning and the end of the experiment. Animals were held in individual pens (2 m 2 and stabilised to a controlled environment facility (22 0 C) for 1 week. The animals were offered ad libitum water and standard pelleted grower rations (3 kg/day 09:00 hrs), WO 00/23601 PCT/AU99/00896 12 and daily residues were recorded. Catheters were placed in ear veins (evc), and 24 hours later sampling commenced. Control pig no pST capsules) blood plasma (10 ml) was collected every 30 min for 3 hours. pST capsules were administered to the ipsilateral ear immediately following serial sampling. Blood (10 ml) was collected via evc (daily 11:00 hrs) while catheters remained patent. Treatment (7 days post administration of pST capsules blood plasma (10 ml) was collected every 30 min for 3 hours.

Slaughter and carcass analysis was performed at about 100 kg live weight 21 days later. pST capsules were then recovered from ears and placed inin vitro culture (for pST assay). The capsule site was also assessed for immune responses lymphocyte infiltration).

The results of measurements of mean (3 hr, 30 min interval) plasma pST concentration of pigs before and 7 days after receiving pST capsules (secreting between 5 and 1000 ng/ml) are shown in Figure 8. As can be seen from Figure 8, it is apparent that plasma pST is reduced in pigs following 1 week exposure to immunoneutral pST (5 100 ng/ml) secreting capsules.

The variability between and within individual plasma pST concentrations appeared to be more apparent during the control serial sampling period. This phenomenon is reflected in the Standard Errors about the mean observed concentrations. Further, the stable baseline and pST pulse intervals (normally 3 4 hrs) were not recognised by computer programs designed to identify hormone pulses. However, stable baselines and distinct pST pulses were observed in animals 1 week post pST casule administration (Figure 9).

The Rate of Gain (ROG) shown by the animals appeared to be responsive to pST capsule secretion in a dose dependent manner (Figure A secretion rate of 30 ng/ml 3 capsules secreting 10 ng/ml each) appears to be the minimum dose required to observe growth rate increases. The majority of evc's remained patent for 21 days at which time, the animals were euthanased with barbituate for carcass analysis. Analysis of carcass back fat (P2 without skin) measurements further indicate that 30 ng.ml is the minimum dose to observe energy repartitioning within 21 days of pST capsule administration (Figure Throughout the experiment there were no indications of adverse reactions, reduction in weight gain or adverse immune responses, including those animals that received 100 capsules.

141429719 13 Example 5: Pilot experiment involving implantation of pST-L61XS in pigs Following example 4, investigations were conducted to assess the effect of the administering optimal pST secretion rates/ capsule numbers to pigs at varying times prior to slaughter 2, 4 and 6 weeks prior to slaughter) on back fat. 8 pigs were used for each treatment as well as 8 control no pST capsules).

The results of the Rate of Gain measurements are provided in Figure 11.

Back fat measurements were obtained following whole carcass chilling (24 hours 4°C) (Figure 12). P2 measurements were recorded at the 12 t h rib 65 mm from the centre of the spinal column. Pigs exposed to capsules secreting pST for 2, 4 and 6 weeks 10 were observed to have significantly reduced back fat. This effect in the 2 and 6 week o *period is approximately a 46% reduction in back fat. The animals exposed to pST IGT capsules for 4 weeks were more variable in their back fat responses, which may relate to a possible failure to recover all the capsules from a number of these animals.

•Loin muscle area in pigs exposed to secreting capsules was only significantly increased 22%) following 6 weeks exposure to pST IGT capsules (Figure 13).

Example 6: Comparative studies of ISS against other secretory signals A comparison of secretory signals (signal sequences) that affect protein secretion rates from transfected cells were performed with different classes of proteins (Table The endogenous signal sequences were maintained within the engineered constructs, in order 20 to ascertain the level of enhanced polypeptide secretion with the ISS proximal to the gene of interest, after removal of the naturally occurring secretory sequences associated with these sequences 05 Table 4 Class Protein Abbrev Hormone Insulin (Human) Ins Cytokine Interleukin 2 (Porcine) IL2 Antigen Outer membrane lipoprotein A (Actinobacilluspleuropneumonia-bacteria) OmlA Extracellular secretory protein (Trichostrongylus colubriformus-nematode) 17kD Chromophore Enhanced Green Fluorescence Protein EGFP 141429719 13a Each of the aforementioned polypeptide encoding gene sequences were incorporated into the expression cassette construct with the ISS immediately proximal to the inserted gene. Following sequence analysis, the L6 cells were transfected and selected with G418 for 7 days prior to identification of stable transfectants. Subsequently, all cell lines were re-sequenced in order to confirm gene constructs before expression analysis was undertaken. Gene expression (RNA), for each class of polypeptide, was analysed with Semi Quantitative Reverse Transcriptase PCR. Transfected cell lines expressing the V 9 representative genes of interest were then recruited for polypeptide expression analysis.

10 The standard format adopted for comparison of polypeptide expression between cell lines employed 5x10 5 cells/2ml of culture media (DMEM supplemented routinely with S 10% FCS), in either 24 well tissue culture plates (2mls of media) or T75 culture flasks of media), in a standard 37°C incubator under 5% CO 2 with a nominated culture time.

The cytokine representative, IL2, was isolated from porcine lymphocytes and 0 inserted into the expression construct after excision of the natural secretory sequence. IL2 concentrations were determined by T cell proliferation assays. Whereby, porcine IL2 dependent T cells (20,000 cells/1001 of media) were exposed, for 24 hours, to media that had been harvested from ISS-IL2 transfected cells (24 hour enrichment). Subsequently, 0* 3 H Thymidine was added to the T-cells and 16 hours later the uptake of radio-labelled 20 Thymidine (counts per minute- cpm) was determined over the course of 3 separate experiments experiments.

0@ SO 5 6 0* S 0 00 Table 5: IL2 +ISS (mean cpm SEM) -ISS (mean cpm SEM) Background proliferation 136 66 161 49 IL2 induced proliferation 12,730 2,540 1,180 157 It is apparent that biologically active IL2 is secreted by the +ISS-IL2 expression construct. However, the construct without ISS (ie wherein secretion was driven by the natural SS to the cytokine), did not increase T cell proliferation to the same extent as the +ISS construct.

A number of antigens were identified as potential candidates for incorporation into the expression construct. However, OmlA and 17kD represent bacterial and parasitic proteins of different sizes and forms that can conveniently be analysed by standard 141429719 13b Enzyme Linked Immunosorbent Assays (ELISA) in order to determine their levels of secretion. In both cases, OmlA- and 17kD-transfected cells were maintained in flasks for 24 hours prior to harvesting the culture media. ELISA plates were coated with antibodies specific for OmlA or 17kD and then harvested culture media (1001) was added to the plates. Following incubation and detection with an enzyme tagged antigen specific antibody, substrates were added in order to ascertain the level of antigen secreted by the transfected cells. Table 6 represents the concentration of ELISA detectable OmlA and 17kD antigen in media secreted by the transfected cells maintained in the T75 format for 24 hours.

0O 00 *e 0

S

S

OS@@

S

0 0

S

S

S.

0

S

Table 6. OmlA 17kD ELISA +ISS -ISS +ISS -ISS Antigen (ng/ml) 5.1 150 <0.1 11.2-218.5 0.1 The EGFP chromophore has been extensively studied and prepared commercially in various constructs for numerous cell-based experiments. The EGFP molecule is also detectable by fluorescence microscopy and ELISA. The EGFP for these studies was 15 selected from the most relevant available products and was incorporated into the expression construct ISS before transfection of L6 cells. Analysis of the cells transfected with the EGFP expression cassette revealed that green fluorescence was present within the cytoplasm of -ISS-EGFP cells. EGFP was not detected, by ELISA or spectrophotometric means, in the media of the -ISS-EGFP cells. By contrast, the +ISS-EGFP cells did not 20 accumulate detectable green fluorescence within the cytoplasm until the cell commenced apoptosis (programmed cell death cell rounding and DNA fragmentation) as represented in Figure 14. EGFP was detected in the media of the +ISS-EGFP cells at 24 hours, in the 24 well format, by specific ELISA and fluorescence spectrometry.

This observation was repeated when the pST and EGFP were placed in tandem in the +ISS expression cassette. The secretion pattern of pST was not affected by the addition of EGFP to theconstruct, and similarly for EGFP expression. This implies that the +ISS expression construct where the ISS is substituted for the natural secretory signal, is capable of secreting different types of biologically active proteins (Figure 14) independently and at the same level of expression as a single gene.

141429719 13c It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore to be considered in all respects as illustrative and not restrictive.

0 0 000 *0

S

0

S

*0

OS

WO 00/23601 PCT/AU99/00896 14 References: Basic et al, (1996) Microencapsulation and transplantation of genetically engineered cells: A new approach to somatic gene therapy. Art. Cells, Blood subs. and Immob. Biotech 24(3): 219-255.

Magari et al, (1997) Pharmacological control of humanised gene therapy system implanted into nude mice. J. Clin. Invest. 100: 2865-2872.

Schrader et al, (1996) Identification of natural monomeric response elements of the nuclear receptor R2R/ROR. They also bind to COUP-TF homodimers.

J. Biol. Chem. 271:19732-19736.

EDITORIAL NOTE FOR 11393/00 THE FOLLOWING SEQUENCE LISTING IS PART OF THE DESCRIPTION THE CLAIMS FOLLOW ON PAGE WO 00/23601 PCT/AU99/00896 1/3 Sequence listing: Applicants: Commonwealth Scientific and Industrial Research Organisation University of Western Sydney (Nepean) Pig Research and Development Corporation Title of the Invention: Delivery system for porcine somatotropin Prior Application Number: PP 6556 Prior Application Filing Date: 1998-10-16 Number of SEQ ID NOs: 3 Software: PatentIn Ver. 2.1 SEQ ID NO: 1 Length: 72 Type: DNA Organism: Homo sapien Sequence: 1 atggccctgt ggatgcgcct cctgcccctg ctggcgctgc tggccctctg gggacctgac ccagccgcag cc SEQ ID NO: 2 Length: 666 Type: DNA Organism: Artificial Sequence Feature: Other Information: Description of Artificial Sequence: ISS-pST gene construct WO 00/23601 WO 0023601PCT/AU99/00896 Sequence: 2 gctagcatgg ccctgtggat cctgacccag ccgcagccct aacgctgttc ttcgggccca gagcgcgcct acatcccgga tgcttctcgg agaccatccc gtggagctgc tgcgcttctc ctcagcaggg tcttcaccaa ctgaaggacc tggaggaggg cgggcaggac agatcctcaa gacgcgctgc ttaagaacta gagacatacc tgcgggtcat tctaga gcgcctcctg cgagatgttt gcacctgcac gggacagagg ggcccccacg gctgctgctc cagcctggtg catccaggcc gcaaacctac cgggctgctc gaagtgtcgc cccctgCtgg ccagctatgc caactggctg tactccatcc ggcaaggacg atccagtcgt tttggcacct ctgatgcggg gacaaatttg tcctgcttca cgcttcgtgg cgctgctggc cactttcttc ccgacaccta agaacgccca aggcccagca gg-zt-Cgggcc caaaccgcgt agctggagga acacaaactt agaaggacct agagcagctg cctctgggga tctgttcgct caaggagttt ggctgccttc gagatcggac cgtgcagttc ctacgagaag tggcagcccc gcgcagtgat gcacaaggct tgccttctag 120 180 240 300 360 420 480 540 600 660 666 SEQ ID NO: 3 Length: 217 Type: PRT Organism: Artificial Sequence Feature: Other Information: Description of Artificial Sequence: ISS-pST peptide sequence Sequence: 3 Met Ala Leu Trp Met Arg Leu Leu Pro Leu Leu Ala Leu Leu Ala Leu Trp Gly Pro Asp Pro Ala Ala Ala Leu Ser Ser Leu Phe Ala Asn Ala 40 Leu Glu Met Phe Pro Ala Met Pro 25 Val Leu Arg Ala Gin His Leu His WO 00/23601 WO 0023601PCT/AU99/00896 Gin Leu Ala Ala Asp Thr Tyr Lys Giu Phe Giu Arg Ala Tyr Ile Pro Glu Ser Gin Arg Tyr Ser Ile Gin Asn 70 Thr Ile Pro Ala Pro Thr Gly Vai Glu Leu Leu Arg Phe Ser Ala Gin Lys Asp Aia Phe Cys Giu Glu Ala Gin 90 Leu Gin Arg Ser Asp Leu Leu Ile Leu Gly Pro Phe Glv Thr Gin Phe Leu Ser 120 Tyr Val Phe Thr Asn 125 Asp Gin Ser Trp 110 Ser Leu Val Leu Giu Giu Ser Asp Arg 130 Ile Vai 135 Arg Giu Lys Leu Giy 145 Gi y Gin Ala Leu Met 150 Gin Glu Leu Giu Gin Ile Leu Asp Asp Ala 180 Lys 165 Leu Thr Tyr Asp Lys 170 Gly Asp Gly Ser 155 Phe Asp Thr Leu Leu Ser Pro Arg Al a 160 As n 175 Phe Lys Ser Leu Lys Asn Cys 190 Lys Asp Leu 195 Arg Phe Val 210 His Lys Ala Giu Giu Ser Ser Cys 215 Thr Tyr Leu Arg Val 200 Ala Phe Met 205 Lys Cys Arg

Claims (22)

1. An expression cassette including a sequence encoding an insulin secretory signal operably linked to a heterologous sequence encoding a polypeptide.

2. An expression cassette according to claim 1, wherein the insulin secretory signal has the amino acid sequence shown as SEQ ID NO:1.

3. An expression cassette according to claim 1, wherein the insulin secretory signal is a modified insulin secretory signal which has one or more amino acid modifications of the amino acid sequence shown as SEQ ID NO:1 and has substantially the 10 same overall biological activity as an insulin secretory signal having the amino acid sequence shown as SEQ ID NO:1.

4. An expression cassette according to any one of claims 1 to 3, wherein the heterologous sequence encodes a polypeptide selected from hormones, cytokines, receptor S. agonists, receptor antagonists, pheromones, and enzymes.

5. An expression cassette according to any one of claims 1 to 3, wherein the heterologous sequence encodes a polypeptide which is normally secreted.

6. An expression cassette according to claim 4 or 5, wherein the polypeptide is a growth hormone.

7. An expression cassette according to claim 6, wherein the polypeptide is 20 somatotropin. S8. An expression cassette according to claim 7, wherein the somatotropin is porcine somatotropin. S* 9. An expression cassette according to any one of claims 1 to 8, further including one or more regulatory elements to enable pulsatile expression of the heterologous sequence. A vector including an expression cassette according to any one of claims 1 to

9.

11. A recombinant cell which includes an expression cassette according to any one of claims 1 to 9.

12. A recombinant cell according to claim 11, wherein the cell is a bacterial, yeast, insect or mammalian cell. a C

13. A recombinant cell according to claim 12, wherein the cell is a mammalian cell. 141429719 16

14. A mammalian cell according to claim 13, wherein the cell is a rat myoblast (L6) cell. A method of producing a polypeptide which includes culturing a recombinant cell of any one of claims 11 to 14 under conditions enabling the expression and secretion of the polypeptide and optionally isolating the polypeptide.

16. A capsule for implantation in a host, the capsule including a semi-permeable membrane encapsulating recombinant cells according to any one of claims 11 to 14.

17. A capsule according to claim 16, wherein the semi-permeable membrane is an alginate-poly-L-lysine-alginate (APA) membrane. 0:10 18. A method of administering a polypeptide to a host, wherein said method includes administering to the host an expression cassette according to any one of claims 1 to 9.

19. A method of administering a polypeptide to a host, wherein the method includes implanting in the host a capsule according to claim 16 or 17.

20. A method according to claim 18 or 19, wherein the host is an animal or human.

21. A method according to claim 20, wherein the host is a livestock animal. *e22. A method according to claim 21, wherein the livestock animal is a pig. •23. A method of administering somatotropin to a pig, wherein the method 20 includes implanting in the pig a capsule including a semi-permeable membrane ••encapsulating recombinant cells, said recombinant cells including and expressing an expression cassette including a sequence encoding an insulin secretory signal operably linked to a heterologous sequence encoding somatotropin, wherein said membrane is Spermeable to the expressed somatotropin.

24. A method according to claim 23, wherein the insulin secretory signal has the amino acid sequence shown as SEQ ID NO:1. A method according to claim 23, wherein the insulin secretory signal is a modified insulin secretory signal which has one or more modifications of the amino acid sequence shown as SEQ ID NO:1 and has substantially the same overall biological activity as an insulin secretory signal having the amino acid sequence shown as SEQ ID NO:1.

26. A method according to any one of claims 23 to 25, wherein the recombinant cells are mammalian cells.

27. A method according to claim 25, wherein the mammalian cells are rat S myoblast (L6) cells. 141429719 17

28. A method according to any one of claims 23 to 27, wherein the semi- permeable membrane is an alginate-poly-L-lysine-alginate (APA) membrane.

29. A method according to any one of claims 23 to 28, wherein the pig is implanted with one or more capsules sufficient to achieve secretion of somatotropin of at least A method according to any one of claims 23 to 29, wherein the somatotropin is porcine somatotropin. 0* 0 0* 4 So 4 0 0 9 556 *S e SI e* S C